Investor FAQ

1.What does Anika Therapeutics do?
2.When was Anika founded?
3.What stock exchange is Anika traded on and what is its stock symbol?
4.When does Anika’s fiscal year end?
5.What is Anika’s competitive advantage?
6.How can I obtain Anika’s investor kit?
7.When is the next financial results release date?
8.How can I receive a copy of Anika’s financial statements?
9.Who serves on Anika’s management team?
10.Who serves on Anika’s Board of Directors?
11.Does Anika pay a dividend on its common stock?
12.Does Anika have a direct stock repurchase program?
13.Who should I contact with questions regarding my shares, transfer of my shares, replacement of a lost stock certificate or change in my address?
14.Who is Anika’s independent accounting firm?
15.Who is Anika’s outside legal counsel?
16.What is Anika’s CUSIP number?
17.How can I contact Anika’s investor relations?
1.What does Anika Therapeutics do?
 Anika Therapeutics develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. HA enhances joint function and coats, protects, cushions and lubricates soft tissues. HA also is present in the skin, where it supports skin structure and elasticity. Anika’s current commercial product lines address the joint health, aesthetic dermatology, ophthalmic, veterinary and anti-adhesion markets.

2.When was Anika founded?
 Anika was founded in 1993.

3.What stock exchange is Anika traded on and what is its stock symbol?
 Anika traded on the Nasdaq Global Select Market under the symbol ANIK.

4.When does Anika’s fiscal year end?
 Anika’s fiscal year ends December 31.

5.What is Anika’s competitive advantage?
 With 20 years of experience in HA technology, Anika has several competitive strengths, including:
• Unique expertise in manufacturing extremely pure, high molecular weight HA-based products, with exceptional safety profiles
• Products based on crosslinked, non-animal sourced HA
• Recognition as a provider of premium, differentiated products

6.How can I obtain Anika’s investor kit?
 Please visit Anika’s Information Request page to receive an investor kit.

7.When is the next financial results release date?
 Please click here for more information.

8.How can I receive a copy of Anika’s financial statements?
 Anika’s financial statements are available for viewing in the “SEC Filings” section of its investor relations website. To receive a hard copy of the Company’s financial statements, please visit the Information Request section of the site and complete the electronic form provided.

9.Who serves on Anika’s management team?
 For detailed information about Anika’s management team, click here.

10.Who serves on Anika’s Board of Directors?
 For detailed information about Anika’s Board of Directors, click here.

11.Does Anika pay a dividend on its common stock?
 Anika has never declared a cash dividend on its common stock, nor does it presently have any plans to initiate a dividend program.

12.Does Anika have a direct stock repurchase program?
 Anika does not have a direct stock purchase program, and presently does not anticipate establishing one.

13.Who should I contact with questions regarding my shares, transfer of my shares, replacement of a lost stock certificate or change in my address?
 For detailed Contact information, please click here.

14.Who is Anika’s independent accounting firm?
 PricewaterhouseCoopers LLP is Anika’s accounting firm.

15.Who is Anika’s outside legal counsel?
 Goodwin Procter LLP serves as the Company’s general legal counsel.

16.What is Anika’s CUSIP number?
 Anika’s CUSIP number is 035255 10 8.

17.How can I contact Anika’s investor relations?
 Please contact:
Sylvia Cheung
Chief Financial Officer
781-457-9000
investorrelations@anikatherapeutics.com